Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Buruli Ulcer Pathogen Detected by Isothermal RPA Assay

By LabMedica International staff writers
Posted on 28 Feb 2019
Buruli ulcer (BU) is a neglected tropical disease caused by Mycobacterium ulcerans. More...
The pathogenesis of BU is linked to the production of a polyketide toxin known as mycolactone, which is cytotoxic and has immunomodulatory properties and presents as nodules, plaques, ulcers and edema.

Nucleic acid amplification of insertion sequence IS2404 by polymerase chain reaction (PCR) is the most sensitive and specific method to detect M. ulcerans, the causative agent of BU. However, PCR is not always available in endemic communities in Africa due to its cost and technological sophistication. Microscopy for acid fast bacilli and culture for M. ulcerans have low sensitivity and histopathology is rarely available in endemic areas.

A team of scientists associated with the Kwame Nkrumah University of Science and Technology (Kumasi, Ghana) evaluated the clinical performance of the M. ulcerans (Mu-RPA) assay was evaluated using DNA extracted from fine needle aspirates or swabs taken from 67 patients in whom BU was suspected and 12 patients with clinically confirmed non-BU lesions. The team developed an isothermal DNA amplification system using the recombinase polymerase amplification (RPA) method.

All samples were tested with both the real-time PCR and the Mu-RPA assay to determine the clinical sensitivity and specificity of the assay using real-time PCR as the reference test. In the case of real-time RPA detection, TwistAmp Exo “Improved Formulation” kit was used. Fluorescence detection at 570 nm for FAM channel was measured and a threshold set by increasing the fluorescence above the three standard deviations over the background detected in the first minute of incubation. The team programmed the T8- fluorometer using the T8-ISO Desktop application to detect the lowest dilutions that met criteria for distinguishing positive samples from negative controls based on serial dilutions of the molecular standard.

The scientists tested all samples by both RPA and real-time PCR and 58 of these samples were confirmed by PCR as BU. Of the 58 confirmed cases, 51 were correctly identified by the RPA assay with seven false negative results giving a sensitivity of 88%. The 21 PCR negative samples were all negative by RPA, specificity of 100% and a 100% positive predictive value (PPV) with a Youden’s index of 88%. When the analysis was stratified by type of sample, the sensitivity and specificity of the RPA for swabs in comparison to PCR were 92% and 100% respectively with a 100% PPV. Similarly, the sensitivity and specificity of FNA samples were 82% and 100% respectively.

The authors concluded that the developed real-time RPA assay for the rapid and accurate detection of M. ulcerans DNA with high sensitivity, specificity and reproducibility was comparable to real-time PCR. It was significantly faster than available real-time PCR methods for detecting M. ulcerans with a run time of 15 minutes, compared to almost two hours for real-time PCR. Potentially the Mu-RPA can be used in a low resource setting closer to the patients when combined with a fast DNA extraction method. The study was published on February 1, 2019, in the journal PLOS NTD.

Related Links:
Kwame Nkrumah University of Science and Technology


New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
Serological Pipet Controller
PIPETBOY GENIUS
New
Staining System
RAL DIFF-QUIK
New
PlGF Test
Quidel Triage PlGF Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.